A co-culture model system to quantify antibody-dependent cellular cytotoxicity in human breast cancer cells using an engineered natural killer cell line

Yagita, 2000, A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation, Leukemia, 14, 922, 10.1038/sj.leu.2401769 Quentmeier, 2019, The LL-100 panel: 100 cell lines for blood cancer studies, Sci. Rep., 9, 8218, 10.1038/s41598-019-44491-x Becker, 2016, Selection and expansion of natural killer cells for NK cell-based immunotherapy, Cancer Immunol. Immunother., 65, 477, 10.1007/s00262-016-1792-y Drexler, 2000, Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma, Leukemia, 14, 777, 10.1038/sj.leu.2401778 Gunesch, 2019, Genome-wide analyses and functional profiling of human NK cell lines, Mol. Immunol., 115, 64, 10.1016/j.molimm.2018.07.015 Koene, 1997, Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype, Blood, 90, 1109, 10.1182/blood.V90.3.1109 Mishima, 2012, High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism, Int. Immunol., 24, 477, 10.1093/intimm/dxs048 Kaptein, 1997, Optimized conditions for the production of recombinant amphotropic retroviral vector preparations, Gene Ther., 4, 172, 10.1038/sj.gt.3300373 Nguyen, 2018, The role of interleukin-2, all-trans retinoic acid, and natural killer cells: surveillance mechanisms in anti-GD2 antibody therapy in neuroblastoma, Cancer Immunol. Immunother., 67, 615, 10.1007/s00262-017-2108-6 Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N. Engl. J. Med., 344, 783, 10.1056/NEJM200103153441101 Ruiz-Saenz, 2018, Targeting HER2 by combination therapies, J. Clin. Oncol., 36, 808, 10.1200/JCO.2017.77.1899 Moasser, 2022, Inactivating amplified HER2: challenges, dilemmas, and future directions, Cancer Res., 82, 2811, 10.1158/0008-5472.CAN-22-1121 Matta, 2018, Development and characterization of a novel luciferase based cytotoxicity assay, Sci. Rep., 8, 199, 10.1038/s41598-017-18606-1 Meléndez, 2022, Novel lectin-based chimeric antigen receptors target Gb3-positive tumour cells, Cell. Mol. Life Sci., 79, 513, 10.1007/s00018-022-04524-7